FDA Clearance Tracker · K223093
Aptiva APS IgG Reagent; Aptiva APS IgM Reagent
Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Dec 17, 2024
Substantially Equivalent
Time to decision
809 days
Received Sep 30, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K223093
- Device name
- Aptiva APS IgG Reagent; Aptiva APS IgM Reagent
- Applicant
- Inova Diagnostics, Inc.
- Applicant location
- San Diego, CA
- Received
- Sep 30, 2022
- Decided
- Dec 17, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5660
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MID. The earliest in FDA's data is K911680, decided Nov 19, 1991.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K223093
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Inova Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Aptiva APS IgA Reagent510(k)
K243979 · Decided Feb 6, 2026 · 410 days after receipt
Device type: System,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi) (MSV) · Laboratory Medicine & Pathology
K213403 · Decided Sep 29, 2023 · 711 days after receipt
Device type: Extractable Antinuclear Antibody, Antigen And Control (LLL) · Laboratory Medicine & Pathology
K200230 · Decided Aug 26, 2021 · 574 days after receipt
Device type: Autoantibodies, Endomysial(Tissue Transglutaminase) (MVM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.